The durable survival benefit and activity in high-risk subgroups support KIMMTRAK as first-line therapy, which could expand its commercial footprint. Traders should monitor prescription trends and potential label expansions.
Price Chart
Executive Summary
Immunocore announced five-year overall survival data from a Phase 3 trial showing KIMMTRAK doubled survival rates in metastatic uveal melanoma patients, with 16% alive at five years versus 8% in the control arm. This represents the longest follow-up data for any T cell engager in a solid tumor, reinforcing KIMMTRAK's clinical benefit across high-risk subgroups.
Key Facts
- KIMMTRAK showed 16% five-year overall survival vs. 8% in control arm (HR 0.67)
- Median OS was 21.6 months vs. 16.9 months in control
- Benefit seen across poor prognostic subgroups including high tumor burden, elevated LDH, and extrahepatic disease
- 44% of KIMMTRAK patients alive at 5 years received only KIMMTRAK, while 86% of control arm survivors later received tebentafusp
- Data presented at AACR 2026 from a Phase 3 randomized trial of 378 patients
Financial Impact
Significant long-term survival benefit strengthens KIMMTRAK's position as standard of care, potentially driving increased adoption and revenue growth
Risk Factors
- Safety profile includes high incidence of cytokine release syndrome (89%) and skin reactions (91%)
- Forward-looking statements subject to clinical, regulatory, and commercial uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276674 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $32.46 $32.18 | ▼ −0.86% | ▼ −0.97% | $29.71 (−8.47%) |
Aug 6, 2026 8w ago | 8-K | $34.50 $34.20 | ▼ −0.87% | ▼ −2.08% | $29.71 (−13.88%) |
May 31, 2026 17w ago | Press Release | $29.13 $28.29 | ▼ −2.88% | ▼ −0.13% | $29.71 (+1.99%) |
Apr 19, 2026 23w ago | Press Release | $31.46 $28.56 | ▼ −9.22% | ▼ −10.13% | $29.71 (−5.56%) |
Apr 8, 2026 25w ago | 144 | $31.85 $31.64 | ▼ −0.66% | ▼ −4.18% | $29.71 (−6.72%) |
Mar 17, 2026 28w ago | Press Release | $30.04 $30.28 | ▲ +0.80% | ▲ +1.51% | $29.71 (−1.10%) |
Feb 25, 2026 31w ago | 8-K | $32.16 $33.73 | ▲ +4.88% | ▲ +5.98% | $29.71 (−7.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access